Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel WE, Serve H.

Blood. 2000 Dec 1;96(12):3907-14.

2.

Role of FLT3 in leukemia.

Gilliland DG, Griffin JD.

Curr Opin Hematol. 2002 Jul;9(4):274-81. Review.

PMID:
12042700
3.

Flt3 receptor tyrosine kinase as a drug target in leukemia.

Schmidt-Arras D, Schwäble J, Böhmer FD, Serve H.

Curr Pharm Des. 2004;10(16):1867-83. Review.

PMID:
15180525
4.

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Sattler M, Scheijen B, Weisberg E, Griffin JD.

Adv Exp Med Biol. 2003;532:121-40. Review.

PMID:
12908554
5.

NOX-driven ROS formation in cell transformation of FLT3-ITD-positive AML.

Jayavelu AK, Moloney JN, Böhmer FD, Cotter TG.

Exp Hematol. 2016 Dec;44(12):1113-1122. doi: 10.1016/j.exphem.2016.08.008. Epub 2016 Sep 22. Review.

PMID:
27666490
6.
7.

Signal transduction of oncogenic Flt3.

Choudhary C, Müller-Tidow C, Berdel WE, Serve H.

Int J Hematol. 2005 Aug;82(2):93-9. Review.

PMID:
16146838
8.

FLT3: ITDoes matter in leukemia.

Levis M, Small D.

Leukemia. 2003 Sep;17(9):1738-52. Review.

PMID:
12970773
9.

Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis.

Strizzi L, Bianco C, Normanno N, Salomon D.

Oncogene. 2005 Aug 29;24(37):5731-41. Review.

PMID:
16123806
10.

From kinases to cancer: leakiness, loss of autoinhibition and leukemia.

Reindl C, Spiekermann K.

Cell Cycle. 2006 Mar;5(6):599-602. Epub 2006 Mar 15. Review.

PMID:
16582613
11.

Genetics of myeloid leukemias.

Kelly LM, Gilliland DG.

Annu Rev Genomics Hum Genet. 2002;3:179-98. Epub 2002 Apr 15. Review.

PMID:
12194988
12.

Anti-apoptotic role of STAT5 in haematopoietic cells and in the pathogenesis of malignancies.

Debierre-Grockiego F.

Apoptosis. 2004 Nov;9(6):717-28. Review.

PMID:
15505414
13.

FLT3-ITD and its current role in acute myeloid leukaemia.

Lagunas-Rangel FA, Chávez-Valencia V.

Med Oncol. 2017 Jun;34(6):114. doi: 10.1007/s12032-017-0970-x. Epub 2017 May 3. Review.

PMID:
28470536
14.

PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML.

Verbiest T, Bouffler S, Nutt SL, Badie C.

Carcinogenesis. 2015 Apr;36(4):413-9. doi: 10.1093/carcin/bgv016. Epub 2015 Mar 6. Review.

15.

Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells.

Turner SD, Alexander DR.

Leukemia. 2006 Apr;20(4):572-82. Review.

PMID:
16482213
16.

FLT3 tyrosine kinase as a target in acute leukemias.

Griffin JD.

Hematol J. 2004;5 Suppl 3:S188-90. Review. No abstract available.

PMID:
15190306
17.

AKT plays a central role in tumorigenesis.

Testa JR, Bellacosa A.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5. Review. No abstract available.

18.

Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory Analysis.

Berenstein R.

Biomark Insights. 2015 Aug 5;10(Suppl 3):1-14. doi: 10.4137/BMI.S22433. eCollection 2015. Review.

19.

Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis.

Grünert S, Jechlinger M, Beug H.

Nat Rev Mol Cell Biol. 2003 Aug;4(8):657-65. doi: 10.1038/nrm1175. Review.

PMID:
12923528

Supplemental Content

Support Center